Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
good annual report ...
they have great plans ... wait a few years and you will laugh about this stock price ... at the moment I think there have to be over 200.000 shares short ... they have also to cover
I think the actual stock price to low? I believe the investors, which bought 526,316 shares for $20 Mio. last week, know there "price target"
From the annual report (the audited 15 Mio. were to low ):
In March 2015, the Company initiated a financing transaction pursuant to which it would sell up to 526,316 shares of the Company’s common stock, to selected investors at $38 per share, for total gross proceeds of approximately $20,000,000. The Shares were sold pursuant to separate subscription agreements between the Company and each Investor. Up to the issuance of the financial statements, $20,000,000 (unaudited) were received from investors.
They've got the "jillions", in their pocket. Manage it wisely. No stopping.....
the next 4 quarters are financed
--> good price!
On March 25, 2015, Cellular Biomedicine Group, Inc. (the “Company”) conducted an initial closing of a financing transaction (the “Financing”) pursuant to which it sold an aggregate of 394,740 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), to selected investors (the “Investors”) at $38.00 per share, for total gross proceeds of approximately $15,000,000.
What do you expect to announce tomorrow?
today before market close we will see short covering ...
new short number will be out after market close --> http://www.nasdaq.com/symbol/cbmg/short-interest
I won´t be short - before tomorrows news
I am expecting a forward split in the not so distance future.
Yes. This thing's headed upward, no denial.....
next Wednesday will be a great day ...
I am waiting eagerly for the presentation!
I think the interim clinical data - phase IIb KOA - will be very good. They won´t presentate bad results on the 2015 Annual Regen Med Invenstor Day!
I am also very excited about the CAR-T cell programs! A lot of investors will realise that CBMG has this technologie (third generation) ... and also the next big market (China).
Good weeks, months, years are ahead!
If it can't break out $49 again, it will pull back from $49. People will sell to take profits. How low it will go? if no news, may be around $30 or lower.
Chart of the Day.
At the Biotech Stock Review.
http://biotechstockreview.ning.com/profiles/blogs/chart-of-the-day-celllular-biomedicine-cbmg-44-65
I am looking to open a position on another immunotherapy company. Any ideas are appreciated...
on the downside we should have a support area between 37 - 39
http://www.stoxline.com/stock_chart/CBMG.gif
at this point yesterday was a normal correction ... rsi was above 90 ...
but I think the people who bought in in the last days have all their shares ... the number of shares which are short will be over 100.000 --> we will see this on the 24/3/15 or earlier when they release news
for short seller this stock is a play with fire ...
Any idea? this stock will go how high? $100?
Pleasant surprise for sure.
CBMG is driving me crazy and makes me rich!
CBMG is the "BAIDU" in Biotechnology in China
© by gold007_2000 (yahoo message board)
great volume!
maybe some shorts had to cover:
http://www.nasdaq.com/symbol/cbmg/short-interest
I am just curious to know what's propelling this enthousiasm and volume increase!
today should be the strongest volume day ever ...
This stock is driving me crazy!
I see next key resistance to be $39. If we manage to break through $39 with volume ( like the one we have today, then $35 becomes our safe support pillow.
We'll see! GLTA!
Does anybody know what drives today's burst?
bingo....
so much, for the resistance at 35$.
I think we will break through the $ 35 when CBMG will publish the 3 month data / phase IIb (KOA)
I believe they will do that this or next week ...
At the moment big players are buying ... looks really, really good!
$35 proved to be a hard to break resistance on Friday.
No stopping. 100 bucks on the way.
It's turning out to be a monster stock
I want to know when this rocket is going to take a breath!
That small buyout? I haven't checked cashflow.
Do you know if their recent buyout is going to generate any cashflow for them?
When the company was OTC they were Eastbridge Investment Group and they held shares in a handful of companies. Interesting they kept shares in WIEI.
Very nice. A 50 bagger in 5 years. I had CBMG while it was still a OTC stock under a different ticker. I plan to hold for the long term.
CBMG could be the next PCYC
watch PCYC .... chart last 5 years ...
I agree. The trials/approvals/patenting/etc, are way down the road. But it's like, ever since they shook hands with the "right" people, and got to ring the end of day market bell, there's no stopping this thing. And they're still doing all the same old form 4 "stuff", probably selling shares at every chance.....
Can you explain it? It just keeps rising....
Here's todays Marketwatch news.
http://eresearch.fidelity.com/eresearch/goto/evaluate/news/basicNewsStory.jhtml?symbols=CBMG&storyid=201502251626MRKTWTCHNEWS_SVC000386&provider=MRKTWTCH&product=NEWS_SVC&hlinks=vnhl
I don't think so at all. This is pie in the sky. It will take several years before it is known if this company is a success.
One more positive news and it will drive this litle puppy to 100's!!!!!
new price target $ 32,50
http://lifetechcapital.com/ltc/wp-content/uploads/2015/02/CBMG-Target-Change-02-17-15.pdf
Rich
I never posted on this thread before as far as I remember. I too received a few shares in worthless spinopps. My impression is that it is hard to arrive at a fair rating of this Company now. It is promising but the market cap may reflest this or more?
Don't remember you posting, if at all, way back then.
They pretty much changed their venue, completely. No more trying to get small public companies, to becoming listed. That never worked out for them at all. For all of their efforts, I think only Wonder went for it, and ended up pathetic(WIEI). I still hold shares from that spinoff, although restricted. Tsingda "chickened" out last second, and I received a "payout" for those spinoff shares.
They've completely changed now, to osteo and other "research".
The change is certainly for the better.
I could sell my shares currently for quite a profit, considering I bought them long ago, when it was only a penny stock. But I'll hold on.
May sell, when it hits a hundred bucks a share. But I think they would probably do a forward split if that happens.
And when I think back, to those old days, when I used to accuse them here, of too much golf playing, and not getting anything done......
I only own 65 shares from those days. I really don't understand why the pps soared so much last summer.
I think they're headed for 100 bucks a share, before they know what happened.
I'm impressed, considering I own a "measly" amount of shares, from the days when they used to try get private companies to go public.....
I see the next short term ressistance at around $34. What do you think?
HUGE NEWSS OUT!!!! CBMG going for shopping! Hold tight and get ready for a ride to $100's....
http://finance.yahoo.com/news/cellular-biomedicine-group-cbmg-acquiring-130000612.html
CFO's impressive CV
CFO Bizuo (Tony) Liu was formerly Corporate Vice President at Alibaba Group (NYSE:BABA) responsible for Alibaba's overseas investments and as General Manager of Corporate Strategy for Microsoft (Nasdaq:MSFT) managing their China investment strategy and corporate strategic planning process
i think this month they will publish the 3 moth data / phase IIb (KOA)
The beast seems to start moving again!
Don.t expect revenues to late 2017 or 2018. per CEO.
Followers
|
35
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
2750
|
Created
|
05/17/07
|
Type
|
Free
|
Moderators |
Cellular Biomedicine Group (NASDAQ: CBMG) is a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases utilizing proprietary cell therapy technologies. We are the result of the acquisition, transfer, commercialization and advancement of thirty years of research and human treatment experience in cellular medicine. Our cellular research and development comes from collaboration among scientists and doctors from the US, Europe and China.
MARKET
Our primary target market is Greater China. Our first two therapy candidates are currently used to treat patients in research studies conducted in China. We are also engaged in a number of pre-clinical studies for other product or therapy candidates, which we believe have the potential to become safe and effective treatment options for a variety of degenerative and debilitating conditions. We believe that the results of our research studies will support expanded preclinical and clinical trials with a larger population of patients, which we expect to carry out through authorized treatment centers throughout Greater China. With the recent acquisition of AG, we added technical services revenue comprised of T Cells Receptor (“TCR”) clonality analysis technology and T Central Memory Cell (“Tcm”) and Dendritic Cell (“DC”) preparation methodologies.
Indication: Knee Osteoarthritis (KOA)
Technology Platform: Human Adipose-Derived Mesenchymal Progenitor Cells (haMPC)
Trial Phase: Clinical Trial Phase IIb, all patients completed treatment as of August 2014
Interim results from phase IIb clinical trial for KOA: klick here
Osteoarthritis is a degenerative disease of the joints. KOA is one of the most common types of osteoarthritis. Pathological manifestation of osteoarthritis is primarily local inflammation caused by immune response and subsequent damage of joints. Restoration of immune response and joint tissues are the objective of therapies.
According to International Journal of Rheumatic Diseases, 2011, 53% of KOA patients will degenerate to the point of disability. Conventional treatment usually involves invasive surgery with painful recovery and physical therapy. As drug-based methods of management are ineffective, the same journal estimates that some 1.5 million patients with this disability will degenerate to the point of requiring artificial joint replacement surgery every year. However, only 40,000 patients will actually be able to undergo replacement surgery, leaving the majority of patients to suffer from a life-long disability due to lack of effective treatment.
About haMPCs
haMPCs are currently being considered as a new and effective treatment for osteoarthritis, with a huge potential market. Osteoarthritis is one of the ten most disabling diseases in developed countries. Worldwide estimates are that 9.6% of men and 18.0% of women aged over 60 years have symptomatic osteoarthritis. It is estimated that the global OA therapeutics market was worth $4.4 billion in 2010 and is forecast to grow at a compound annual growth rate (“CAGR”) of 3.8% to reach $5.9 billion by 2018.
In order to bring haMPC-based KOA therapy to market, our market strategy is to: (a) establish regional laboratories that comply with cGMP standards in Shanghai and Beijing that meet Chinese regulatory approval; and (b) file joint applications with Class AAA hospitals (own commentary: press release from 09.02.2015 (klick here): We look forward to working with PLAGH as a long-term partner as we evaluate paths to commercialization,” commented Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group.) to use haMPCs to treat KOA in a clinical trial setting.
Our KOA therapy is not surgically invasive – it uses a small amount (30ml) of adipose tissue obtained via liposuction from the patient, which is cultured and re-injected into the patient. The injections are designed to induce the body’s secretion of growth factors promoting immune response and regulation, and regrowth of cartilage. The down-regulation of the patient’s immune response is aimed at reducing and controlling inflammation which is a central cause of KOA.
We believe our proprietary method, subsequent haMPC proliferation and processing know-how will enable haMPC therapy to be a low cost and relatively safe and effective treatment for KOA. Additionally, banked haMPCs can continue to be stored for additional use in the future.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |